In the last few years, there has been an increase in research around using psychedelic drugs, like LSD and magic mushrooms, as treatments for mental health conditions. And recently, two Canadian companies working in the sphere have gotten a special designation from a big U.S. regulator that could fast-track the development and review of their drugs.
Sean Silcoff is a journalist with The Globe’s Report on Business. He has been looking at recent developments in these companies and how that fits into the bigger picture of investor excitement around these drugs.
Questions? Comments? Ideas? Email us at thedecibel@globeandmail.com
The lost art of human pinsetting
The myth and the reality of Newfoundland’s giant squids
The complicated art of political cartoons, with Brian Gable
The man accused of selling toxic substances used for suicide
What a bad back tells us about Canada’s chronic pain problem
School shutdowns, hospital delays and a massive strike in Quebec
Can carbon capture solve emissions problems for oil and gas?
Cervical cancer is on the rise in Canada
Why climate change is driving up the cost of your insurance
How a Ukrainian teen fought to get her brother back from Russia
Your personal finance questions answered, with Rob Carrick
What Google’s deal with Canada means for the rest of the world
Ranking Canada’s most livable cities
Tensions over Israel-Hamas war and free speech on campus
Money laundering, crypto trading and Canada’s richest man
Europe’s far-right is moving into the mainstream
The historic rise of rental costs in Canada
How an Ontario city is taking a new approach to homelessness
The Canadian scientist at the centre of the OpenAI drama
Gaza’s underground tunnels
Create your
podcast in
minutes
It is Free
The Daily
Morning Wire
Up First
Today, Explained
WSJ What’s News